Managing comorbidities of inflammatory rheumatic diseases;Behandlung der komorbiditäten entzündlich-rheumatischer erkrankungen

Internist

Volumn 52, Issue 6, 2011, Pages 688-696

  De Groot, K ^a   Marker Hermann E ^b  

^a Klinikum Offenbach GmbH   (Germany)

^b DR HORST SCHMIDT KLINIKEN   (Germany)

Author keywords

Cardiovascular comorbidity; Infection; Inflammatory autoimmune disease; Neoplastic comorbidity; Osteoporosis

Indexed keywords

CARDIOVASCULAR DISEASE; COMORBIDITY; CONCURRENT INFECTION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; HUMAN; INFLAMMATION; OSTEOPOROSIS; REVIEW; RHEUMATIC DISEASE; TUMOR;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; DIPHOSPHONATES; HUMANS; INFLAMMATION; RHEUMATIC DISEASES;

EID: 79959789155     PISSN: 00209554     EISSN: 14321289     Source Type: Journal    
DOI: 10.1007/s00108-010-2769-0     Document Type: Review

References (31)

1. Atzeni F, Turiel M, Hollan I et al (2010) Usefulness of cardiovascular biomarkers and cardiac imaging in systemic rheumatic diseases. Autoimmun Rev 9:845-848
2. Baecklund E, Askling J, Rosenquist R et al (2004) Rheumatoid arthritis and malignant lymphomas. Curr Opin Rheumatol 16:254-261 (Pubitemid 38530494)
3. Bernatsky S, Ramsey-Goldman R, Rajan R et al (2005) Non-Hodgkin's lymphoma in systemic lupus erythematosus. Ann Rheum Dis 64:1507-1509 (Pubitemid 41623867)
4. Bertsias G, Ioannidis JP, Boletis J et al (2008) EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR standing committee for international clinical studies including therapeutics. Ann Rheum Dis 67:195-205
5. Booth AD, Almond MK, Burns A et al (2003) Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 41:776-784 (Pubitemid 36396745)
6. Carroll MB, Forgione MA (2010) Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action. Clin Rheumatol 29:1021-1029
7. Cervera R, Khamashta MA, Font J et al (2003) Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 82:299-308 (Pubitemid 37229465)
8. Choi HK, Hernan MA, Seeger JD et al (2002) Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 359:1173-1177 (Pubitemid 34304256)
9. Culleton BF, Larson MG, Wilson PW et al (1999) Cardiovascular disease and mortality in a communitybased cohort with mild renal insufficiency. Kidney Int 56:2214-2219 (Pubitemid 30004750)
10. Dachverband Osteologie (2006) Prophylaxe, Diagnostik und Therapie der Glukokortikoid-induzierten Osteoporose. Langfassung. www.dv-osteologie.org
11. Dachverband Osteologie (2009) DVO-Leitlinie 2009 zur Prophylaxe, Diagnostik und Therapie der Osteoporose bei Erwachsenen. Osteologie 18:304-328
12. Faurschou M, Mellemkjaer L, Sorensen IJ et al (2009) Increased morbidity from ischemic heart disease in patients with Wegener's granulomatosis. Arthritis Rheum 60:1187-1192
13. Fischer-Betz R, Halle M, Schneider M (2010) Inflammation-related cardiovascular morbidity: Pathophysiology and therapy. Z Rheumatol 69:680-684, 686-688
14. Guillevin L, Cordier JF, Lhote F et al (1997) A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 40:2187-2198 (Pubitemid 28016415)
15. Holle JU, Gross WL, Latza U et al (2010) Improved outcome of 445 Wegener's granulomatosis patients in a German vasculitis center over four decades. Arthritis Rheum 63:257-266
16. Little MA, Nightingale P, Verburgh CA et al (2010) Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 69:1036-1043
17. McCarey DW, McInnes IB, Madhok R et al (2004) Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 363:2015-2021 (Pubitemid 38781100)
18. Meyer-Olson D, Hoeper K, Schmidt RE (2010) Infectious complications of biologic therapy in patients with rheumatoid arthritis. Z Rheumatol 69:879-888
19. Morgan MD, Turnbull J, Selamet U et al (2009) Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody-associated vasculitides: a matched-pair cohort study. Arthritis Rheum 60:3493-3500
20. Peters MJ, Symmons DP, McCarey D et al (2010) EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69:325-331
21. Peters MJ, Visman I, Nielen MM et al (2010) Ankylosing spondylitis: a risk factor for myocardial infarction? Ann Rheum Dis 69:579-581
22. Reinhold-Keller E, Beuge N, Latza U et al (2000) An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 43:1021-1032 (Pubitemid 30368179)
23. Ridker PM, Hennekens CH, Buring JE et al (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342:836-843 (Pubitemid 30165206)
24. Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I et al (2009) Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther 11:R109
25. Ruyssen-Witrand A, Fautrel B, Saraux A et al (2010) Cardiovascular risk induced by low-dose corticosteroids in rheumatoid arthritis: A systematic literature review. Joint Bone Spine 77:246-251
26. Solomon DH, Curhan GC, Rimm EB et al (2004) Cardiovascular risk factors in women with and without rheumatoid arthritis. Arthritis Rheum 50:3444-3449 (Pubitemid 39488668)
27. Strangfeld A, Hierse F, Rau R et al (2010) Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 12:R5
28. Tatsis E, Reinhold-Keller E, Steindorf K et al (1999) Wegener's granulomatosis associated with renal cell carcinoma. Arthritis Rheum 42:751-756 (Pubitemid 29171996)
29. Thomas CF, Limper AH (2004) Pneumocystis pneumonia. N Engl J Med 350:2487-2498
30. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group (2005) Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 352:351-361
31. Westhoff G, Weber C, Zink A (2006) Comorbidity in rheumatoid arthritis of early onset. Effects on outcome parameters. Z Rheumatol 65:487-488, 490-4, 496